Plant Compounds Show Promise Against Arthritis Target
Computer modeling identifies four phytochemicals that may inhibit JAK proteins involved in rheumatoid arthritis.
Updated on Nov. 4, 2026 in Arthritis
Researchers used in-silico molecular docking to screen 10 ligands against JAK family proteins and identified quercetin, kaempferol, catechin, and naringenin as candidate JAK inhibitors for rheumatoid arthritis. The findings were published as accepted early-access research on November 4, 2026.
Why it matters
Nearly half of rheumatoid arthritis patients continue to have moderate to severe disease activity despite guideline-adherent treatment, and standard JAK inhibitors carry adverse side effects. Natural compounds with strong binding affinity could offer a basis for safer alternatives, though they remain at the computational stage.
Quercetin's binding affinity of -9.3 kcal/mol toward JAK2 exceeded the reference drug baricitinib's -8.2 kcal/mol in computer simulations, while quercetin's selectivity index of 1.18 indicates limited isoform discrimination. Whether these modeled interactions translate to biological activity remains untested.
The details
The team docked 10 ligands against JAK family proteins and compared their binding energies with those of established drugs such as baricitinib and peficitinib. Quercetin, kaempferol, catechin, and naringenin emerged as the strongest candidates, and the authors call for further preclinical evaluation of these phytochemicals as modulators of the JAK/STAT pathway.
Timeline
November 4, 2026: Study published as accepted early-access research.
Health Landscape
The study extends the existing JAK inhibitor class, which includes approved drugs baricitinib and peficitinib, by searching for plant-derived alternatives with comparable or stronger JAK2 binding. Its candidates remain computational leads that would need laboratory and clinical validation before they could join that drug class.
For people living with rheumatoid arthritis, the findings do not change current treatment, since the compounds have only been evaluated by computer modeling. The research points toward possible future options that could reduce reliance on JAK inhibitors with known side effects.
The takeaway
Computer screening can narrow large sets of natural compounds to a few promising candidates before costly lab work begins. Readers should treat these results as early-stage leads rather than treatment advice, and should follow established rheumatoid arthritis care guidance in the meantime.
Further reading
For more on how researchers are approaching joint inflammation, explore our Arthritis coverage.
Source note: This article includes information reported by Nature.
